Tirzepatide Cost & Access: Vials, Pens, Medicare and the Price Moves of 2025 and 2026

Read This First

This page is not built on clinical trial evidence. Cost and access are commercial and legal facts, not scientific findings. They come from the approved product's label, the manufacturer's announcements, the FDA's compounding record and the Medicare programme documents, and for this drug they have changed on timescales of months since late 2024.

Tirzepatide has a list price, two brand names, four presentations, a manufacturer that sells it directly to the public, a government website that lists it, and since 1 July 2026 a Medicare programme that covers it for obesity for the first time.12 It also had, until early 2025, a large compounded market that the FDA has since closed.

This page publishes no prices. Tirzepatide's list price, cash prices and copays have moved repeatedly since 2024 and any figure printed here would be wrong within months. What follows is what determines the money, which for this drug means which channel a person is standing in and which name is on the box.

How Tirzepatide Pricing Works

Why There Is No Single Price

There are at least six distinct prices for the same molecule. The insured patient with a covered indication pays a plan copay after prior authorisation. The Medicare beneficiary in the GLP-1 Bridge pays a flat monthly copayment. The cash-paying patient buying single-dose vials or the KwikPen from the manufacturer's own platform pays a self-pay price that steps up with dose. The cash-paying patient going through the government's direct-to-consumer site pays a negotiated figure that the November 2025 agreement said would fall over two years. The patient on compounded product pays a pharmacy's price for something that is not tirzepatide as approved. And the buyer of a research vial pays a vendor for something that may not be tirzepatide at all.12

The list price is the number least likely to be the one paid, and the number most often quoted.

Why Did My Cost Change When the Dose Did?

Because the self-pay channels price by strength. Tirzepatide is escalated from 2.5 mg through 5, 7.5, 10, 12.5 to 15 mg, and both the manufacturer's platform and the government site have priced the starting doses below the maintenance doses.1 A quote at 2.5 mg is a quote for the four weeks the label says are for initiation only.3 The Medicare Bridge is the exception: its copayment is flat and does not rise with dose, which is one of the few things about it that is simpler than commercial coverage.2

Which Dose Is Being Paid For?

In SURMOUNT-1, 5 mg produced 15.0 percent weight loss, 10 mg 19.5 percent and 15 mg 20.9 percent.4 In channels that price by strength, the top dose costs the most and adds the least. The label's instruction to "consider treatment response and tolerability when selecting the maintenance dosage" is a clinical instruction with a financial consequence.3

Insurance

Coverage Depends on the Indication, Not the Molecule

Mounjaro is approved for type 2 diabetes; Zepbound for chronic weight management and, since December 2024, for moderate-to-severe obstructive sleep apnoea in adults with obesity.3 The same pen is covered or not depending on which diagnosis is attached to it. Diabetes coverage is broad. Obesity coverage is not: many commercial plans and most state Medicaid programmes exclude anti-obesity drugs as a class, and where they are covered, prior authorisation with BMI thresholds, documented comorbidities and sometimes step therapy is the norm.

Does the Sleep Apnoea Indication Change Anything?

Yes, for some people. Obstructive sleep apnoea is a medical diagnosis that plans do not exclude the way they exclude obesity, and Medicare Part D was able to cover Zepbound for it before it could cover Zepbound for weight. A person with both obesity and moderate-to-severe sleep apnoea may have a covered route that a person with obesity alone does not. That is a fact about billing codes rather than pharmacology, and it is why the indication mattered commercially.

The Medicare GLP-1 Bridge

This is the largest change in access in the drug's history, and it is temporary. Under a pilot announced by the Centers for Medicare and Medicaid Services following the November 2025 agreements with Lilly and Novo Nordisk, Medicare covers GLP-1 drugs for obesity from 1 July 2026 to 31 December 2027. Enrolment in a Part D plan is required. Eligibility is a body mass index of 27 or higher with a qualifying condition, or 35 or higher without one. The covered tirzepatide presentation is the Zepbound KwikPen only, not single-dose pens or vials. The prescriber submits a prior authorisation to a central contractor rather than to the Part D plan, and the beneficiary pays a flat monthly copayment at the pharmacy that does not vary with dose.2

Three limits are worth knowing before relying on it. The copayment does not count toward the Part D deductible or the annual out-of-pocket cap. Beneficiaries receiving the low-income subsidy cannot apply it to Bridge drugs. And the programme ends in December 2027, with a possible successor in 2028 that has not been designed; for a maintenance drug, an 18-month coverage window is a decision about what happens in month 19.2 Someone already on tirzepatide for diabetes, cardiovascular risk or sleep apnoea continues through their regular Part D plan at that plan's price, which may be higher.

Prior Authorisation and Appeals

For commercial obesity coverage, the criteria are usually the label's: BMI of 30 or more, or 27 with a weight-related condition, and a documented attempt at lifestyle change. Denials are commonly for missing documentation rather than ineligibility, and an appeal that supplies it succeeds more often than one that argues. A plan that excludes obesity drugs as a class cannot be appealed on clinical grounds, because the exclusion is not a clinical decision.

Can HSA or FSA Funds Be Used?

For a prescription for the approved product, on the ordinary basis that it is a prescribed medicine, yes, including cash purchases through the manufacturer's or the government's platform. For compounded product with a prescription, generally the same. For research vials, no: there is no prescription and no medical expense, and the account holder carries the consequences.

Cash Pay and the Direct Channels

What Changed?

Two things, in sequence. In 2024 Lilly introduced single-dose vials of Zepbound sold through its own platform at self-pay prices below the pen's list price, which made a cash channel that had not existed. In November 2025 Lilly and the US government announced an agreement under which the drug is listed on a government direct-to-consumer site, Medicare covers it for obesity through the Bridge, states may extend Medicaid access, and the manufacturer's own self-pay prices were lowered again.1 The multi-dose KwikPen that the agreement centred on was approved in January 2026.3

The consequence for a cash-paying buyer is that the approved product is now available without insurance at prices that, whatever they are in a given month, are set by the manufacturer and the government rather than by a telehealth service reselling a compounded copy.

What About the Compounded Alternative?

It was cheaper because it skipped everything the approved product includes, and since March 2025 it has been unlawful to make at scale. The FDA declared the tirzepatide shortage resolved on 19 December 2024, enforcement discretion ended in February and March 2025, and the agency's position is that a resolved shortage means the drug is commercially available and copies may not be regularly compounded.5 Lilly sued compounders and telehealth companies through 2025, and the FDA issued warning letters to telehealth firms in September 2025 and again, 30 of them, in March 2026.67

A compounded price today is a price for a product that is either a copy the pharmacy is not permitted to make regularly, or a "personalised" variant offered to argue it is not a copy. The discount is the sum of what it lacks. The sourcing page covers what that is.

What the Money Buys

Where Does the Spread Between Channels Come From?

ONPEPS publishes no prices; read this as reasoning about cost structure rather than a measured breakdown. Each row down removes something the row above included, and the direct-to-consumer row is new: it is the first time an approved GLP-1 for obesity has been sold to the public by its manufacturer at a self-pay price without a compounded copy underneath it.

What Does the Full Course Cost, Not the First Month?

The starting dose lasts four weeks and is not a maintenance dose.3 Escalation to 15 mg took 20 weeks in the trials.4 In dose-priced channels, the monthly cost at the destination is the number to plan around, not the introductory one.

What Happens Financially If It Stops?

SURMOUNT-4 answered this directly: a year after withdrawal, participants had regained 14 percent of body weight, about two thirds of what they lost, while those who continued lost a further 5.5 percent.8 The relevant financial question is therefore an open-ended commitment rather than the price of a course, and for a Medicare beneficiary it is specifically what happens when the Bridge ends. No trial has tested tapering or intermittent use as a way of reducing that cost.

The Spending Decision

What Result Is Being Paid For?

The best-documented weight loss of any approved drug: about 20 percent at the higher doses over 72 weeks, more than semaglutide in a head-to-head trial, sustained for three years, with a near-elimination of progression to diabetes in people with prediabetes.4910 That result was produced by trial-supplied drug of verified identity, escalated on a fixed schedule, with a lifestyle programme and medical monitoring. The approved product delivers the first of those; the prescriber and the patient deliver the rest.

What is not yet being paid for is a demonstrated reduction in heart attacks and strokes in people without diabetes. Semaglutide has that trial; tirzepatide's is ongoing, and its diabetes outcomes trial showed non-inferiority to dulaglutide rather than superiority.11 A person choosing tirzepatide over semaglutide is paying for more weight loss with equivalent, not greater, proven cardiovascular protection.

Is It Cheaper Than Semaglutide?

The two manufacturers have moved their prices in step since November 2025, and both drugs are in the Medicare Bridge at the same copayment.2 In any given channel the difference is small relative to the difference in effect, which favours tirzepatide on weight and semaglutide on outcomes evidence. The ONPEPS semaglutide cost page covers the other side of that comparison.

What Should Be Asked Before Paying?

• Is this Mounjaro or Zepbound, a compounded product, or a research vial? The answer determines everything else.

• If insured: is obesity a covered indication on this plan, and if not, is sleep apnoea or diabetes?

• If on Medicare: am I eligible for the Bridge, is the prescription for the KwikPen, and what is the plan for January 2028?2

• If paying cash: what is the monthly cost at the maintenance dose I am likely to reach, not at 2.5 mg?

• If compounded: what patient-specific reason is documented for not using the approved product, and which pharmacy is making it?

• Does anyone here earn commission on product sales?

What Would Change This Page

2028, Oral Drugs, and Outcomes

Three things are scheduled. The Medicare Bridge ends on 31 December 2027 and whether a permanent programme replaces it is undecided. Oral GLP-1 drugs are reaching the market and were priced into the November 2025 agreements; an oral tirzepatide does not exist, and an oral competitor at a lower price would change the comparison. And SURMOUNT-MMO, the cardiovascular outcomes trial in obesity without diabetes, would settle whether tirzepatide's extra weight loss buys extra protection.1

Generics and Patent Timing

Tirzepatide's core patents run into the mid-2030s. No generic is in prospect in the United States within this page's horizon, and the price moves of 2025 and 2026 came from negotiation and competition rather than from patent expiry.

A Note on Price Comparisons

Figures circulate comparing compounded or research tirzepatide with the approved product per milligram. The comparison is between products the law does not treat as interchangeable and the buyer cannot verify as identical, and since March 2025 one of them is not lawfully made at scale. ONPEPS does not make it.

Related ONPEPS Coverage

• Tirzepatide library entry: the trials, the label and what the outcomes data do and do not show

• Tirzepatide sourcing and quality: after the shortage, what compounded and gray-market product now is

• Semaglutide cost, insurance and access

• Retatrutide cost and access: why there is no price, and no legal route

Sources

1. Eli Lilly and Company. Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans. Press release, 6 November 2025. investor.lilly.com

2. Fortiér J. Some Medicare beneficiaries can now get popular obesity drugs for a flat monthly copay. NPR. Published 6 May 2026, updated 1 July 2026. Describes the Medicare GLP-1 Bridge programme, its dates, eligibility, covered presentations and limits. npr.org

3. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection: prescribing information. Revised August 2026. DailyMed. dailymed.nlm.nih.gov

4. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. Open access. pubmed.ncbi.nlm.nih.gov/35658024

5. US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Drug Alerts and Statements. Content current as of 1 April 2026. fda.gov

6. Eli Lilly and Company. Lilly statement on Mounjaro (tirzepatide) compounding litigation. Investor news release. investor.lilly.com

7. US Food and Drug Administration. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. Press announcement, 3 March 2026. fda.gov

8. Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. Paywalled. pubmed.ncbi.nlm.nih.gov/38078870

9. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36. Paywalled. pubmed.ncbi.nlm.nih.gov/40353578

10. Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958-971. Paywalled. pubmed.ncbi.nlm.nih.gov/39536238

11. Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393(24):2409-2420. Paywalled. pubmed.ncbi.nlm.nih.gov/41406444

Not Medical or Financial Advice

Tirzepatide is a prescription medicine, and treatment decisions belong with a prescriber who has read its label. Coverage decisions belong with the plan or the programme. Nothing on this page is a recommendation to buy or not to buy anything; it is an account of what determines what the money would be spent on.

Sources verified 16 September 2026. Prices, coverage criteria, the direct-to-consumer channels and the Medicare programme all change frequently. Re-verify before relying on anything here.